Executive Summary
NYHA functional class collapses the sickest half of the heart failure population into two bins. A patient walking a block with dyspnea and a patient on continuous milrinone are both "NYHA class III–IV," yet their one-year mortality differs by an order of magnitude and their management has nothing in common. Two complementary systems were built to fix this.
The INTERMACS patient profiles subdivide NYHA class III–IV into seven clinical profiles, ordered from critical cardiogenic shock (Profile 1, "crash and burn") to advanced but stable NYHA class III (Profile 7) [1,6]. Each profile carries an explicit time frame for definitive intervention — hours for Profile 1, weeks to months for Profiles 3 and 4, variable for Profiles 5 and 6. Three modifiers refine the assignment: TCS (temporary circulatory support), A (arrhythmia), and FF (frequent flyer) [1]. The profiles were built for mechanical circulatory support registries, but they discriminate outcomes in ambulatory patients who will never see a device: in the REVIVAL registry, the 12-month composite of death, durable MCS, or urgent transplant was 39%, 27%, 24%, and 14% across Profiles 4, 5, 6, and 7 [3].
The formal definitions of advanced heart failure answer a different question — not "how sick is this patient right now" but "has this patient crossed out of stage C." The 2018 HFA-ESC position statement requires all four of: persistent NYHA III–IV symptoms; severe cardiac dysfunction; congestion or low-output episodes or malignant arrhythmias driving more than one unplanned visit or hospitalization in 12 months; and severe exercise impairment — every one of them despite optimal guideline-directed treatment [1].
The diuretic criteria sit inside the older ACCF/AHA list, carried forward verbatim into the HFA-ESC statement's comparison table: "Recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose >160 mg/day and/or use of supplemental metolazone therapy" [1,4]. That single line is the most nephrology-facing entry in the advanced heart failure literature, and it is the one a nephrologist is positioned to detect months before a cardiologist does — because we are the ones writing the metolazone.
Prognosis justifies the effort. In a complete geographic population, 13.7% of all heart failure patients met the 2018 ESC advanced criteria, and median survival from the moment those criteria were met was 12.2 months [5]. More than half of them had mid-range or preserved ejection fraction, and survival did not differ by EF [5].
Advanced heart failure is not a diagnosis a patient arrives with. It is a threshold that gets crossed quietly, usually in an outpatient clinic, and usually while someone is adjusting diuretics. The escalation to 160 mg of furosemide equivalent, or the decision to add metolazone, is a documented marker of that crossing — not a routine titration.
1. Why NYHA Fails at the Severe End
The New York Heart Association classification has survived since 1928 because it is fast, free, and communicates something real. Its weakness is resolution. Classes I and II cover a broad, relatively well population. Classes III and IV compress everyone else — from a patient who tires after a block to a patient in cardiogenic shock — into two categories that cannot be used to time an intervention.
INTERMACS was created explicitly to solve this. The STS Intermacs teaching materials state the rationale plainly: the profiles were initially developed to overcome the limitations of the NYHA classification for patients being evaluated for mechanical circulatory support, and were intended to discern relative differences among patients with advanced NYHA class III and IV symptoms [2].
So the answer to the question "what classification has seven sub-classes for NYHA III/IV" is the INTERMACS patient profiles. They are not a replacement for NYHA. They are a magnifying glass applied to its bottom two classes.
NYHA class is a symptom descriptor. An INTERMACS profile is a time-to-intervention descriptor. When you assign a profile you are not only saying how sick the patient is — you are stating how long you believe you have.
2. The INTERMACS Profiles: Seven Sub-Classes of NYHA III–IV
The profiles were first published in the INTERMACS registry reports and formalized by Stevenson and colleagues in 2009 [6,7]. The descriptions below follow the HFA-ESC 2018 position statement's reproduction of that table, which is the most accessible authoritative version [1].
2.1 The Seven Profiles
| Profile | Name | Shorthand | Defining features | Time frame for intervention |
|---|---|---|---|---|
| 1 | Critical cardiogenic shock | "Crash and burn" | Life-threatening hypotension despite rapidly escalating inotropic support; critical organ hypoperfusion, often confirmed by worsening acidosis and/or lactate | Within hours |
| 2 | Progressive decline | "Sliding on inotropes" | Declining function despite IV inotropic support — worsening renal function, nutritional depletion, inability to restore volume balance. Also describes decline in patients unable to tolerate inotropes | Within a few days |
| 3 | Stable but inotrope-dependent | "Dependent stability" | Stable BP, organ function, nutrition, and symptoms on continuous IV inotropes (or temporary circulatory support), but repeated failure to wean due to recurrent symptomatic hypotension or renal dysfunction | Elective, over weeks to a few months |
| 4 | Resting symptoms | "Frequent flyer" | Can be stabilized close to normal volume status but has daily symptoms of congestion at rest or during ADL. Doses of diuretics generally fluctuate at very high levels | Elective, over weeks to a few months |
| 5 | Exertion intolerant | "Housebound" | Comfortable at rest and with ADL but unable to engage in any other activity; lives predominantly within the house. No congestive symptoms, but may have underlying refractory elevated volume status, often with renal dysfunction | Variable — depends on nutrition, organ function, activity |
| 6 | Exertion limited | "Walking wounded" | Comfortable at rest and with ADL and minor activities outside the home, but fatigues after the first few minutes of any meaningful activity | Variable — depends on nutrition, organ function, activity level |
| 7 | Advanced NYHA class III | "Placeholder" | Without current or recent episodes of unstable fluid balance; living comfortably with meaningful activity limited to mild physical exertion | Transplantation or circulatory support may not currently be indicated |
2.2 The Three Modifiers
Modifiers are appended to the numeric profile and are frequently omitted in practice, which loses information.
| Modifier | Meaning | Which profiles it can modify |
|---|---|---|
| TCS | Temporary Circulatory Support — IABP, ECMO, TandemHeart, Impella, Levitronix, BVS 5000/AB5000. In-hospital patients only | 1, 2, 3 (in hospital) |
| A | Arrhythmia — recurrent ventricular tachyarrhythmias contributing substantially to clinical compromise, including frequent ICD shocks or need for external defibrillation, usually more than twice weekly | Any profile |
| FF | Frequent Flyer — an outpatient requiring frequent emergency visits or hospitalizations for diuretics, ultrafiltration, or temporary IV vasoactive therapy | 3 (if at home), 4, 5, 6. Rarely 7 |
The Frequent Flyer modifier is defined by recurrent presentations for diuretics or ultrafiltration. A patient cycling through the infusion center or the ED for IV Lasix is, by definition, INTERMACS 4-FF or 5-FF — an advanced heart failure designation — even though nobody has used the word "advanced" in the chart.
2.3 Boundary Rules That Are Commonly Missed
- Profile 7 is fragile. The STS definition is explicit: any decompensation requiring intravenous diuretics or hospitalization within the previous month should make the patient Profile 6 or lower [2]. A single recent IV diuretic visit demotes a Profile 7.
- Profiles 4 and 5 shuttle. The ESC table notes that some patients may shuttle between 4 and 5 [1].
- Profile 5 can be more dangerous than Profile 4. If nutritional status and organ function are marginal, Profile 5 patients may be more at risk than INTERMACS 4 and require definitive intervention [1]. The lower number is not uniformly the sicker patient.
- Profile 2 does not require inotropes. It also describes a patient with refractory volume overload in whom inotropic infusions cannot be maintained because of tachyarrhythmias, ischemia, or other intolerance [2].
2.4 Prognostic Performance in Ambulatory Patients
The profiles were designed for device registries, and their behavior in ambulatory patients — particularly Profiles 6 and 7 — was uncertain until the REVIVAL registry addressed it directly [3].
REVIVAL enrolled 400 outpatients at 21 MCS and transplant centers: 33 Profile 4 (8%), 83 Profile 5 (21%), 155 Profile 6 (39%), and 129 Profile 7 (32%) [3]. Across profiles there were no differences in age, sex, ejection fraction, blood pressure, or GDMT use — the profiles were capturing something those variables do not [3].
| INTERMACS profile | 12-month composite (death, durable MCS, or urgent transplant) |
|---|---|
| Profile 4 | 39% |
| Profile 5 | 27% |
| Profile 6 | 24% |
| Profile 7 | 14% |
p = 0.004 across profiles [3]
Lower profile was also associated with more hospitalizations, greater frailty, and more impaired functional capacity and quality of life [3].
Fourteen percent of ambulatory INTERMACS Profile 7 patients reached death, durable MCS, or urgent transplant within twelve months [3]. That is the best profile in the advanced range.
3. The Formal Definitions of Advanced Heart Failure
Four bodies have published definitions. They overlap heavily but differ in structure: the ESC statement is a conjunctive four-criterion definition, while the ACCF/AHA and HFSA documents are lists of triggers.
3.1 HFA-ESC 2018 — The Four Criteria (Current European Standard)
All four criteria must be present despite optimal guideline-directed treatment [1]:
- Severe and persistent symptoms of heart failure — NYHA class III (advanced) or IV.
- Severe cardiac dysfunction, defined by at least one of:
- LVEF ≤30%, or - Isolated RV failure (e.g., ARVC), or - Non-operable severe valve abnormalities, or - Non-operable severe congenital abnormalities, or - Persistently high (or increasing) BNP or NT-proBNP with evidence of severe diastolic dysfunction or LV structural abnormalities per the ESC definitions of HFpEF and HFmrEF.
- Episodes of congestion or low output: pulmonary or systemic congestion requiring high-dose IV diuretics (or diuretic combinations), or low-output episodes requiring inotropes or vasoactive drugs, or malignant arrhythmias — causing more than 1 unplanned visit or hospitalization in the last 12 months.
- Severe impairment of exercise capacity: inability to exercise, or 6-minute walk distance <300 m, or peak VO₂ <12–14 mL/kg/min, estimated to be of cardiac origin.
Two qualifications in the original are frequently dropped and materially change who qualifies [1]:
- Extra-cardiac organ dysfunction due to heart failure (cardiac cachexia, liver or kidney dysfunction) or group 2 pulmonary hypertension may be present but is not required.
- Criteria 1 and 4 can be met in patients whose limitation is partly non-cardiac — severe pulmonary disease, non-cardiac cirrhosis, or most commonly renal disease of mixed etiology. These patients still warrant the same intensity of evaluation, though their therapeutic options are usually more limited.
Criterion 2 accommodates preserved and mid-range EF through the natriuretic peptide and diastolic dysfunction pathway. This is not a theoretical allowance: when these criteria were applied to a complete population, 43.4% of advanced heart failure patients had HFpEF and 14.3% had HFmrEF [5]. Advanced heart failure is not a reduced-EF disease.
3.2 ACCF/AHA — Clinical Events and Findings (Where the 160 mg Threshold Lives)
The ACCF/AHA lists eleven clinical events and findings useful for identifying advanced heart failure. Reproduced from the HFA-ESC comparison table [1], citing the 2009 focused update and the 2013 ACCF/AHA guideline [4,8]:
- Repeated (≥2) hospitalizations or ED visits for HF in the past year
- Progressive deterioration in renal function (e.g., rise in BUN and creatinine)
- Weight loss without other cause (e.g., cardiac cachexia)
- Intolerance to ACE inhibitors due to hypotension and/or worsening renal function
- Intolerance to beta-blockers due to worsening HF or hypotension
- Frequent systolic blood pressure <90 mmHg
- Persistent dyspnea with dressing or bathing requiring rest
- Inability to walk 1 block on level ground due to dyspnea or fatigue
- Recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose >160 mg/day and/or use of supplemental metolazone therapy
- Progressive decline in serum sodium, usually to <133 mEq/L
- Frequent ICD shocks
Item 9 is the diuretic criterion. Note its exact construction: it is either the dose threshold or the addition of metolazone — not both, and the metolazone limb has no dose qualifier at all. Starting metolazone in a patient already on a loop diuretic satisfies this criterion on its own.
3.3 HFSA — Indicators Triggering Referral
The Heart Failure Society of America defines advanced heart failure as progressive and/or persistent severe signs and symptoms despite optimized medical, surgical, and device therapy, with the progressive decline primarily driven by the heart failure syndrome [9]. Its referral triggers, in the setting of optimal medical and electrical therapy [1]:
- Need for IV inotropic therapy for symptomatic relief or to maintain end-organ function
- Peak VO₂ <14 mL/kg/min or <50% of predicted
- 6MWT distance <300 m
- ≥2 HF admissions in the last 12 months
- More than 2 unscheduled visits (ED or clinic) in the last 12 months
- Worsening right heart failure and secondary pulmonary hypertension
- Diuretic refractoriness associated with worsening renal function
- Circulatory–renal limitation to RAAS inhibition or beta-blocker therapy
- Progressive/persistent NYHA class III–IV symptoms
- Increased 1-year mortality (e.g., 20–25%) predicted by HF survival models (SHFM, HFSS)
- Progressive renal or hepatic end-organ dysfunction
- Persistent hyponatremia (serum sodium <134 mEq/L)
- Recurrent refractory ventricular tachyarrhythmias; frequent ICD shocks
- Cardiac cachexia
- Inability to perform ADL
Three of these fifteen are renal. A nephrologist following a cardiorenal patient will usually see diuretic refractoriness with worsening renal function, and circulatory–renal limitation to RAAS inhibition, before anyone else does.
3.4 Comparison
| Feature | HFA-ESC 2018 [1] | ACCF/AHA [4,8] | HFSA [9] |
|---|---|---|---|
| Structure | Conjunctive — all 4 required | List of triggers | List of triggers |
| EF requirement | ≤30% or RV/valve/congenital or NP + diastolic criteria | Not specified in the list | Not specified in the list |
| Explicit diuretic dose threshold | No — states "high-dose IV diuretics or diuretic combinations" | Yes — >160 mg/day furosemide equivalent and/or metolazone | No — states "diuretic refractoriness with worsening renal function" |
| Exercise threshold | 6MWD <300 m; pVO₂ <12–14 | Inability to walk 1 block | 6MWD <300 m; pVO₂ <14 or <50% predicted |
| Hyponatremia threshold | Not a criterion | <133 mEq/L | <134 mEq/L |
| Hospitalization threshold | >1 unplanned visit/admission in 12 mo | ≥2 in past year | ≥2 admissions or >2 unscheduled visits in 12 mo |
| Includes HFpEF | Yes, explicitly | Not addressed | Not addressed |
4. The Diuretic Criteria — A Nephrology Reading
This section expands §3.2 item 9, because it is the criterion most likely to be crossed in a nephrology clinic and least likely to be recognized as a staging event.
4.1 What 160 mg/day Furosemide Equivalent Actually Means
The threshold is expressed in oral furosemide equivalents per day. Using the conversion table maintained in this vault (see Loop Diuretic Route and Equivalence):
| Agent and route | Approximate clinical equivalent | Dose reaching the 160 mg/day threshold |
|---|---|---|
| Furosemide PO | 40 mg | 160 mg/day (e.g., 80 mg BID) |
| Furosemide IV | 20 mg | 80 mg/day IV |
| Bumetanide PO | 1 mg | 4 mg/day (e.g., 2 mg BID) |
| Bumetanide IV | 1 mg | 4 mg/day |
| Torsemide PO | 20 mg | 80 mg/day |
Conversion source: Michigan Medicine inpatient diuretic guideline, as adopted in the vault reference. Treat these as starting equivalents, not a promise of equal patient response.
Stated in the doses actually written in clinic: furosemide 80 mg twice daily, torsemide 40 mg twice daily, or bumetanide 2 mg twice daily each sit exactly at the advanced heart failure threshold. These are not unusual prescriptions in a cardiorenal practice. That is the point — the criterion is calibrated to catch a dose that feels routine.
A patient maintained on bumetanide 2 mg BID has met an ACCF/AHA advanced heart failure criterion. A patient on bumetanide 4 mg BID — a dose that appears in this vault's own case material — is at roughly 320 mg/day furosemide equivalent, double the threshold.
4.1a Why 160 mg — The Survival Data Behind the Threshold
The threshold is not arbitrary. It traces to a 1,354-patient cohort of advanced systolic heart failure referred to a single center, in which patients were divided into quartiles of total daily loop diuretic dose in furosemide equivalents: 0–40, 41–80, 81–160, and >160 mg [16].
| Quartile | Daily furosemide equivalent | Survival |
|---|---|---|
| 1 | 0–40 mg | 83% |
| 2 | 41–80 mg | 81% |
| 3 | 81–160 mg | 68% |
| 4 | >160 mg | 53% |
The cohort was 76% male, mean age 53 ± 13 years, mean ejection fraction 24 ± 7%, mean diuretic dose equivalence 107 ± 87 mg [16]. The highest quartile had a smaller ejection fraction, lower serum sodium and hemoglobin, and higher BUN and creatinine — that is, the confounding ran in the obvious direction [16].
After adjustment for age, sex, ischemic etiology, ejection fraction, BMI, pulmonary capillary wedge pressure, peak oxygen consumption, beta-blocker use, ACEi/ARB use, digoxin, statin, sodium, BUN, creatinine, hemoglobin, cholesterol, systolic blood pressure, and smoking, diuretic quartile remained an independent predictor of mortality: quartile 4 versus quartile 1, HR 4.0 (95% CI 1.9–8.4) [16].
The HFSA stage D statement cites this directly when it states that patients who require high diuretic doses, especially those on 160 mg furosemide per day or higher, have poor survival [9,16].
This is an observational cohort. High diuretic dose is overwhelmingly a marker of disease severity, not a proven cause of death, and the adjustment — extensive though it is — cannot exclude residual confounding by severity. The correct inference is not "give less diuretic." It is: a patient who has arrived at >160 mg/day belongs to a group whose survival was 53%, and that fact should trigger evaluation, not reassurance.
4.2 The Metolazone Limb
The metolazone limb has no dose floor. Use of supplemental metolazone therapy satisfies criterion 9 on its own [1,4]. Sequential nephron blockade is a marker of loop diuretic failure, and loop diuretic failure in heart failure is an advanced-disease event regardless of how well it works.
Two caveats worth carrying, both already documented in this vault:
- The premise that metolazone uniquely retains efficacy at low eGFR is not directly evidenced, and chlorthalidone has demonstrated efficacy at eGFR levels once considered prohibitive — see Water Pills and Diuretics: Evidence Review.
- In the only randomized comparison of its kind, 61 patients with heart failure resistant to IV furosemide were assigned to dapagliflozin 10 mg daily or metolazone 5–10 mg daily for 3 days. Weight fell 3.0 ± 2.5 kg with dapagliflozin and 3.6 ± 2.0 kg with metolazone — a mean difference of 0.65 kg (95% CI −0.12 to 1.41, P = 0.11). Decreases in plasma sodium and potassium and rises in urea and creatinine were smaller with dapagliflozin [10].
So metolazone is a staging trigger, and it is also a drug whose incremental benefit over alternatives in the refractory setting is modest and whose metabolic cost is real.
4.3 The Criteria That Overlap With Cardiorenal Syndrome
Four advanced heart failure criteria are, functionally, descriptions of cardiorenal syndrome:
| Criterion | Source | Cardiorenal translation |
|---|---|---|
| Progressive deterioration in renal function | ACCF/AHA [1,4] | Type 2 CRS |
| Intolerance to ACEi due to hypotension and/or worsening renal function | ACCF/AHA [1,4] | Circulatory–renal limitation |
| Diuretic refractoriness with worsening renal function | HFSA [1,9] | Decongestion failure |
| Circulatory–renal limitation to RAAS inhibition or beta-blocker therapy | HFSA [1,9] | The GDMT ceiling |
See Cardiorenal Syndrome and RHC Comprehensive Interpretation Guide §12 for the hemodynamic basis of diuretic resistance.
4.4 Kidney Trajectory After the Advanced Threshold Is Crossed
In the Olmsted County advanced heart failure cohort (n = 936, mean age 77), eGFR distribution at the time advanced criteria were met was: 22% <30, 22% 30–44, 23% 45–59, and 32% ≥60 mL/min/1.73 m² [11]. Kidney function then declined faster: 7.6% annual decline before advanced HF versus 10.9% after, with greater decreases in patients with diabetes and preserved ejection fraction [11]. An eGFR <30 at the time of advanced heart failure diagnosis was associated with worse survival compared with eGFR ≥60 (adjusted HR 1.30, 95% CI 1.07–1.57) [11].
Nearly a quarter of patients already have eGFR <30 when they meet advanced heart failure criteria, and the rate of renal decline accelerates after that point [11]. The nephrologist is not a downstream consultant in advanced heart failure — the kidney trajectory inflects at the same moment the cardiac one does.
5. "I NEED HELP" — The Referral Mnemonic
Baumwol's 2017 mnemonic is the most widely used bedside screen for advanced heart failure referral and is reproduced in the HFA-ESC position statement [1,12]:
| Letter | Marker | Definition |
|---|---|---|
| I | Inotropes | Previous or ongoing requirement for dobutamine, milrinone, dopamine, or levosimendan |
| N | NYHA class / natriuretic peptide | Persisting NYHA class III or IV and/or persistently high BNP or NT-proBNP |
| E | End-organ dysfunction | Worsening renal or liver dysfunction in the setting of heart failure |
| E | Ejection fraction | Very low ejection fraction <20% |
| D | Defibrillator shocks | Recurrent appropriate defibrillator shocks |
| H | Hospitalizations | More than 1 hospitalization with heart failure in the last 12 months |
| E | Edema / escalating diuretics | Persisting fluid overload and/or increasing diuretic requirement |
| L | Low blood pressure | Consistently low BP with systolic <90 to 100 mmHg |
| P | Prognostic medication | Inability to up-titrate (or need to decrease/cease) ACEi, beta-blockers, ARNIs, or MRAs |
The second E — edema and escalating diuretics — is the mnemonic's expression of the 160 mg / metolazone criterion, stated without a numeric threshold. When a number is wanted, use the ACCF/AHA figure from §3.2.
"I NEED HELP" is a screen, not a definition. A positive letter prompts a referral conversation; it does not establish advanced heart failure. The formal diagnosis still requires the HFA-ESC four criteria (§3.1) applied after guideline-directed therapy has genuinely been optimized. Record how many markers are present, not merely whether any are.
6. Prognosis Once the Threshold Is Crossed
Three complementary datasets define what advanced heart failure costs.
Population-based (Olmsted County, 2007–2017). Of 6,836 adults with heart failure, 936 (13.7%) met the 2018 ESC advanced criteria [5]. At the time criteria were met, 42.3% had HFrEF, 14.3% HFmrEF, and 43.4% HFpEF. Median time from advanced HF diagnosis to death was 12.2 months (IQR 3.7–29.9). Mean hospitalization rate in the first year was 2.91 per person-year (95% CI 2.78–3.06). There were no differences in all-cause mortality or hospitalization by EF; advanced HFpEF carried a lower risk of cardiovascular mortality than advanced HFrEF (HR 0.79, 95% CI 0.65–0.97) [5].
Administrative claims (OptumLabs, 2009–2019). Among 60,197 US adults identified by a validated advanced heart failure algorithm (2 HF hospitalizations plus 1 additional sign within 12 months), mean age 73, median survival was 2.0 years (IQR 0.4–5.5) [13]. Adjusted mortality was higher in older, male, non-Hispanic White, and rural patients. Advanced therapies were used less in older patients and in women. Black patients were more likely to receive an LVAD (P = 0.010) but less likely to receive a transplant than White patients (P = 0.034) [13].
Ambulatory, referred, on optimal therapy (REVIVAL). In 400 ambulatory patients at MCS/transplant centers — mean LVEF 21%, median 6-minute walk 341 m, 92% INTERMACS Profiles 5–7 — the composite of death, durable VAD, or urgent transplant occurred in 22% at 1 year and 37% at 2 years, with death alone in 8% and 16% [14]. Patients surviving to 2 years maintained GDMT intensity with no decline in health-related quality of life [14].
Median survival of 12.2 months (population) versus 2.0 years (claims) versus 84% two-year survival (REVIVAL) is not a contradiction — it is selection. The population cohort captures everyone, including the elderly and the HFpEF majority; the claims algorithm requires two hospitalizations; REVIVAL enrolled ambulatory patients referred to advanced centers and eligible for a device. Quote the number that matches the patient in front of you, and say which cohort it comes from.
7. Applying This in Clinic — A Practical Sequence
- Assign an INTERMACS profile, with modifiers. Ask what the time frame for intervention is, not just how symptomatic the patient is. Record FF if the patient is cycling through the ED or infusion center for diuretics or ultrafiltration.
- Compute the daily furosemide equivalent. Convert whatever agent is prescribed to oral furosemide equivalents (§4.1). Note whether 160 mg/day has been reached.
- Note any thiazide-type add-on. Metolazone satisfies the ACCF/AHA criterion independent of dose.
- Run "I NEED HELP" and count the markers (§5).
- Test the four HFA-ESC criteria formally (§3.1) — and be honest about whether GDMT was genuinely optimized or merely attempted.
- Check the renal trajectory. eGFR slope, not a single value. Acceleration of decline is itself information [11].
- If criteria are met, refer — and say why in the referral. "Advanced heart failure by HFA-ESC criteria; INTERMACS 4-FF; furosemide equivalent 320 mg/day plus metolazone; eGFR fell from 42 to 29 over 8 months" transmits more than "please evaluate for advanced therapies."
References
- Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(11):1505-1535. PMID: 29806100
- Pagani FD. STS Intermacs Patient Profiles. Society of Thoracic Surgeons Learning Center teaching materials. Profile definitions as originally published in references 6 and 7.
- Kittleson MM, Shah P, Lala A, et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: a report from the REVIVAL Registry. J Heart Lung Transplant. 2020;39(1):16-26. PMID: 31522912
- Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary. Circulation. 2013;128(16):1810-1852. PMID: 23741057
- Dunlay SM, Roger VL, Killian JM, et al. Advanced heart failure epidemiology and outcomes: a population-based study. JACC Heart Fail. 2021;9(10):722-732. PMID: 34391736
- Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant. 2009;28(6):535-541. PMID: 19481012
- Kirklin JK, Naftel DC, Stevenson LW, et al. INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant. 2008;27(10):1065-1072. PMID: 18926395
- Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol. 2009;53(15):e1-e90. PMID: 19358937
- Fang JC, Ewald GA, Allen LA, et al. Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. J Card Fail. 2015;21(6):519-534. PMID: 25953697
- Yeoh SE, Osmanska J, Petrie MC, et al. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J. 2023;44(31):2966-2977. PMID: 37210742
- Quiram BJ, Killian JM, Redfield MM, et al. Changes in kidney function after diagnosis of advanced heart failure. J Card Fail. 2023;29(12):1617-1625. PMID: 37451601
- Baumwol J. "I Need Help" — a mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017;36(5):593-594. PMID: 28258792
- Subramaniam A, van Houten H, Redfield MM, et al. Advanced heart failure characteristics and outcomes in commercially insured U.S. adults. JACC Heart Fail. 2023;11(11):1595-1606. PMID: 37589611
- Aaronson KD, Stewart GC, Stevenson LW, et al. Optimizing triage of ambulatory patients with advanced heart failure: 2-year outcomes from REVIVAL. JACC Heart Fail. 2024;12(10):1734-1746. PMID: 38970587
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895-e1032. PMID: 35363499
- Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759-1764. PMID: 16765130
Related Reading
- Stage C2D Heart Failure — The ambulatory transition from stage C to stage D: the 2026 JACC Heart Failure position statement, its criteria, and its prognosis.
- Advanced Heart Failure: Therapeutics and Evidence — What the trials actually show once a patient crosses out of stage C: GDMT at the ceiling, decongestion, hemodynamics, MCS, and palliative care.
- HFpEF Diagnostic Criteria 2025 — relevant because most advanced heart failure is not HFrEF.
- Cardiorenal Module index